DaVita Inc. Set to Report Q3 Earnings, Analysts Predict 27% Profit Boost
DaVita Inc. (DVA), a leading provider of kidney dialysis services based in Denver, Colorado, is set to release its fiscal third-quarter earnings after market close on Wednesday, October 29. Analysts anticipate a profit of $3.29 per share, marking a 27% increase from the year-ago quarter.
DVA, with a market capitalization of $9 billion, operates kidney dialysis centers and related lab services. Despite a notable year-over-year dip in normalized non-acquired treatment and adjusted operating margins, analysts remain cautiously optimistic. They predict a potential upside of 20.4% in DVA stock, with an average price target indicating a 'Hold' rating overall.
Looking ahead, analysts expect DVA's EPS to rise to $10.93 in fiscal 2025, up 12.9% from fiscal 2024. This growth is projected to continue, with EPS expected to reach $12.73 in fiscal 2026, a 16.5% year-over-year increase. However, DVA's stock performance has lagged behind the S&P 500 Index and the Health Care Select Sector SPDR Fund over the past 52 weeks.
DaVita Inc. is expected to report its fiscal third-quarter earnings on October 29, with analysts predicting a significant profit increase. Despite recent underperformance, analysts maintain a cautious optimism, forecasting steady EPS growth in the coming years.
